IND Maintenance During Ongoing Clinical Trials in the United States
IND Maintenance During Ongoing Clinical Trials in the United States Maintaining IND Compliance During Ongoing Clinical Trials in the U.S. Introduction Once an Investigational New Drug (IND) application is authorized by the U.S. Food and Drug Administration (FDA), sponsors must maintain compliance throughout the duration of clinical development. IND maintenance includes submitting amendments, annual reports,…
Read More “IND Maintenance During Ongoing Clinical Trials in the United States” »